A Fuc3S4S substituted oligoglycosaminoglycan mixture and a pharmaceutically acceptable salt thereof, the Fuc3S4S is 3,4-disulfated-L-fucose-1-yl, the Fuc3S4S substituted oligoglycosaminoglycan mixture is a mixture of oligomeric homologous glycosaminoglycan compounds having a structure represented by Formula (I), in Formula (I): Ring A is β-D-glucuronic acid group or β-D-glucosyl group, wherein, R 1 is -COO - , -CH 2 OH, - COR 10 , R 10 is independently substituted or unsubstituted linear or branched C1-C6 alkyl, C7-C12 aralkyl; Ring B is substituted β-D-2-amino-2-deoxy-galactosyl, wherein, R 2 is -COCH 3 or -H; R 3 and R 4 are independently -H or -SO 3 - ; Ring C is α-L-fucosyl, wherein, R 5 , R 6 and R 7 are independently -H or -SO 3 - , and based on molar ratio, the α-L-fucosyl wherein R 5 is -H, R 6 and R 7 are -SO 3 - , i.e. 3,4-disulfated-L-fucose-1-yl, accounts for not less than 75% of the total α-L-fucosyl; R 8 is the structure represented by Formula (III): in Formula (III): Ring A is a β-D-glucuronic acid group or β-D-glucosyl, Ring A' is 4-deoxy-4-threo-hex-4-enopyranosyluronic acid group, R 1 in the formula is defined as above; Ring C is α-L-fucosyl, wherein, R 5 , R 6 and R 7 are defined as above; R 9 is a structure represented by Formula (IV) or Formula (V): in Formula (IV) and (V), Ring B is substituted α or β- D-2-amino-2-deoxy-galactosyl, B' is substituted 2-amino-2-deoxy- galactitol, glycosamine or N- substituted glucosamine, wherein, R 3 and R 4 are defined as above; R 11 is hydroxy, amino, C1-C6 alkylamino, C7-C12 arylamino; When R 8 is the structure of Formula (III), R 9 is the structure of Formula (IV) or Formula (V); n is an integer of 2-20; and based on molar ratio, the compound that n is 4-9 accounts for not less than 75% of the total compounds; the oligomeric homologues glycosaminoglycan mixture has a weight average molecular weight (Mw) of 4.5-9 kD, and a polydispersity index (PDI) of less than or equal to 1.6. Ring A is β-D-glucuronic acid group or β-D-glucosyl group, wherein, R 1 is -COO - , -CH 2 OH, - COR 10 , R 10 is independently substituted or unsubstituted linear or branched C1-C6 alkyl, C7-C12 aralkyl; Ring B is substituted β-D-2-amino-2-deoxy-galactosyl, wherein, R 2 is -COCH 3 or -H; R 3 and R 4 are independently -H or -SO 3 - ; Ring C is α-L-fucosyl, wherein, R 5 , R 6 and R 7 are independently -H or -SO 3 - , and based on molar ratio, the α-L-fucosyl wherein R 5 is -H, R 6 and R 7 are -SO 3 - , i.e. 3,4-disulfated-L-fucose-1-yl, accounts for not less than 75% of the total α-L-fucosyl; R 8 is the structure represented by Formula (III): Ring A is a β-D-glucuronic acid group or β-D-glucosyl, Ring A' is 4-deoxy-4-threo-hex-4-enopyranosyluronic acid group, R 1 in the formula is defined as above; Ring C is α-L-fucosyl, wherein, R 5 , R 6 and R 7 are defined as above; R 9 is a structure represented by Formula (IV) or Formula (V): Ring B is substituted α or β- D-2-amino-2-deoxy-galactosyl, B' is substituted 2-amino-2-deoxy- galactitol, glycosamine or N- substituted glucosamine, wherein, R 3 and R 4 are defined as above; R 11 is hydroxy, amino, C1-C6 alkylamino, C7-C12 arylamino; When R 8 is the structure of Formula (III), R 9 is the structure of Formula (IV) or Formula (V); n is an integer of 2-20; and based on molar ratio, the compound that n is 4-9 accounts for not less than 75% of the total compounds; the oligomeric homologues glycosaminoglycan mixture has a weight average molecular weight (Mw) of 4.5-9 kD, and a polydispersity index (PDI) of less than or equal to 1.6. <EOS>